3 Reasons SOLV is Risky and 1 Stock to Buy Instead
ST. PAUL, Minn. , Dec. 23, 2025 /PRNewswire/ -- Solventum  (NYSE: SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company...
New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care
ST. PAUL, Minn. , Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative...
/Solventum%20Corp-%20healthcare%20phone-by%20ipopba%20via%20iStock.jpg)
Solventum has delivered stronger performance than the Nasdaq Composite over the past year, reinforcing analysts’ moderate optimism regarding the stock’s forward outlook.
This Buffett stock has been one of his few misfires, and that situation doesn't look poised to change.
1 Unpopular Stock That Should Get More Attention and 2 We Ignore
Check out these three stocks that are up more than 20% in 2025 and just increased their buyback capacity. One stock experiencing strong growth stands out.